Axsome stock: buy or sell?
December 6th, 2019
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders.
Should I buy Axsome stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best moment to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
These 2 buy setups are elegible for Axsome stock now:
|New all-time high||Yes|
|New 52 week high||Yes|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Axsome Therapeutics stock a buy?
Financial institutions and banks post stock ratings everyday.At Stocks2.com, we collected 12 ratings published for AXSM stock in the last 30 days. The general sentiment of these ratings is bullish for AXSM stock, with 12 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
Axsome stock analysis
After climbing to all-time highs several times in past weeks, Axsome Therapeutics skyrocketed 5.06% to $45.43.
After several days of continuous hikes in past weeks, Axsome Therapeutics skyrocketed 5.06% to $45.43. Since last October when AXSM stock price broke up the SMA200d line, it gained $27.19 (149.07%). Since SMA50d and SMA100d crossed up on December 4th, AXSM price slid a -0.39%. On Dec 4th, AXSM hit new all time highs, pushing higher previous ATH of $47.24 recorded on Tuesday. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
Axsome Therapeutics ended this week at $45.43 after reaching a new all time high ($47.68) and skyrocketed an exceptional 15.39%. With this, it's been 5 climbing weeks in a row, soaring a 88.22%.
If you observe the weekly chart, price finally broke over the resistance at $24.94 and continued climbing. Since price and SMA40w lines crossed up by mid October, AXSM climbed $27.29 (150.44%). Since this week when SMA10w and SMA20w crossed up, AXSM price gained $6.06 per share (15.39%).
Axsome stock price history
Axsome IPO was on November 19th, 2015 at $9.00 per share1. Since then, AXSM stock surged a 404.80%, with a yearly average of 101.20%. If you had invested right after AXSM's IPO a $1,000 in Axsome stock in 2015, it would worth $4,048.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Axsome stock historical price chart
AXSM stock reached all-time highs on December/4 with a price of $47.68.
Axsome stock price target is $21.90Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. We detected 9 price forecasts for AXSM stock released in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-24||HC Wainwright||Set Price Target||n/a||$30.00||-|
|2019-3-5||HC Wainwright||Set Price Target||n/a||$15.00||-|
|2019-3-28||BTIG Research||Raises Target||n/a||$25.00||-|
|2019-3-26||HC Wainwright||Set Price Target||n/a||$18.00||-|
|2019-3-21||Cantor Fitzgerald||Raises Target||$16.00||$25.00||56.3%|
|2019-3-15||Cantor Fitzgerald||Raises Target||$13.00||$16.00||23.1%|
Financials and fundamental analysis
Earnings date and Earnings per ShareAfter presenting its last earnings report on March, Axsome . As soon as we get its actual EPS from the earnings report, we will extend this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual revenues report draw of to M USD. When comparing vs , , profit margin (that is, the net income divided by revenues) a to .
Quarterly financial resultsReported quarter earnings marked $-9.60 million with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, Axsome Therapeutics sales marked a neutral movement and remained stable a nan%. Looking back to recent quarterly results, Axsome posted 7 positive quarters in a row.
Axsome ownershipWhen you are planning to invest in shares of a stock, it's always worth to overview its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Axsome Therapeutics, 27.32% of all outstanding shares are owned by its staff.
In case of Axsome stock, 17.42% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AXSM stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$1.6 B||$341.4 M||$188.6 M|
|Total shares||34.5 M||114.2 M||55.0 M|
|Float shares||23.8 M||96.5 M||41.5 M|
|- Institutional holdings (%)||17.4%||95.2%||72.8%|
|- Insider holdings (%)||27.3%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Friday, December 6th, 2019|
|Day range||$42.44 - $45.68|
|Average true range||$3.10|
|50d mov avg||$26.53|
|100d mov avg||$26.12|
|200d mov avg||$22.33|
Axsome performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare Axsome performance to PDL BioPharma and Pieris Pharmaceuticals: